Solanum incanum extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1187 views | HTML 1916 views | ?
Sebastian Yu1,2, Hamm-Ming Sheu3 and Chih-Hung Lee4
1Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
3Department of Dermatology, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
4Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Chih-Hung Lee, email: [email protected]
Keywords: melanoma, SR-T100, solamargine, Solanum incanum, immunotherapy
Received: March 06, 2017 Accepted: September 05, 2017 Published: October 04, 2017
Melanoma, a cancer derived from melanocytes, is one of the most chemoresistant cancers and tends to metastasize. Once it metastasizes, the prognosis is poor. Even with the recent advancement of targeted therapy and immunotherapy, the prognosis remains discouraging. SR-T100, a Solanum incanum extract, shows anticancer effects against several cancers; however, its therapeutic efficacy against melanoma and established metastasis remains unknown. In this study, we showed that SR-T100 induces apoptosis, DNA damage, and G0/G1 cell cycle arrest in murine B16 melanoma cells in vitro. In vivo, intralesional injection of SR-T100 decreased the tumor size of the regional melanoma in the foot pad. Moreover, intraperitoneal injection of SR-T100 inhibited the growth and the number of established melanoma metastases in the lungs. Our study highlights SR-T100 as a potential novel treatment for established tumors from regional and metastatic melanoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.